Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. Its ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. The company also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation. It focuses on providing ophthalmology programs and medications for glaucoma, wet age-related macular degeneration, diabetic macular edema, and chronic dry eye disease. The company's medicine business includes medications used in several therapeutic areas, including oncology, autoimmunity, chronic infectious diseases, and endocrine and metabolic diseases; and urology business comprises a series of injectable erectile dysfunction formulations for patients that are refractory to or are otherwise unable to take phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil. In addition, it develops PPS-DR (pentosan polysulfate sodium delayed-release) formulations as alternatives to Elmiron for patients diagnosed with interstitial cystitis; and develops and sells therapeutic alternatives to Daraprim, Thiola, and Calcium Disodium Versenate. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.
http://www.priceseries.com/trade/IMMY-Imprimis-Pharmaceuticals-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018080620180827.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments